Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma
Autor: | Oluwole Fadare, Franco Rongioletti, Andy C. Hsi, Katy Smoot, Rossitza Lazova, Matthew J. Powell, Harriet H. Kluger, Heather Anderson, Erin H. Seeley, Sara D'Hallewin, Luca Pilloni, Christine Camacho, Arlene S. Rosenberg, Iliana Tantcheva-Poor, Omobolade Obadofin, Ralitza Gueorguieva |
---|---|
Přispěvatelé: | Lazova, R., Smoot, K., Anderson, H., Powell, M. J., Rosenberg, A. S., Rongioletti, F., Pilloni, L., D'Hallewin, S., Gueorguieva, R., Tantcheva-Poor, I., Obadofin, O., Camacho, C., Hsi, A., Kluger, H. H., Fadare, O., Seeley, E. H. |
Rok vydání: | 2019 |
Předmět: |
Adult
Male Proteomics medicine.medical_specialty Pathology Skin Neoplasms Histology Nevi and melanomas Adolescent Dermatology Mass Spectrometry Pathology and Forensic Medicine Diagnosis Differential Machine Learning Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Biopsy medicine Humans Child Melanoma Nevus neoplasms Aged Aged 80 and over Training set Tissue microarray Malignant melanoma Mass spectrometry medicine.diagnostic_test business.industry Middle Aged medicine.disease Paraffin embedded tissue Benign nevus Child Preschool 030220 oncology & carcinogenesis Histopathology-guided mass spectrometry Female Histopathology Dermatopathology business |
Zdroj: | Journal of Cutaneous Pathology. 47:226-240 |
ISSN: | 1600-0560 0303-6987 |
Popis: | Purpose Distinguishing benign nevi from malignant melanoma using current histopathological criteria may be very challenging and is one the most difficult areas in dermatopathology. The goal of this study was to identify proteomic differences, which would more reliably differentiate between benign and malignant melanocytic lesions. Methods We performed histolpathology - guided mass spectrometry (HGMS) profiling analysis on formalin-fixed, paraffin embedded tissue samples to identify differences at the proteomic level between different types of benign nevi and melanomas. A total of 756 cases, of which 357 cases of melanoma and 399 benign nevi, were included in the study. The specimens originated from both biopsies (376 samples) and tissue microarray (TMA) cores (380 samples). After obtaining mass spectra from each sample, classification models were built using a training set of biopsy specimens from 111 nevi and 100 melanomas. The classification algorithm developed on the training data set was validated on an independent set of 288 nevi and 257 melanomas from both biopsies and TMA cores. Results In the melanoma cohort, 239/257 (93%) cases classified correctly in the validation set, 3/257 (1.2%) classified incorrectly, and 15/257 (5.8%) classified as indeterminate. In the cohort of nevi, 282/288 (98%) cases classified correctly, 1/288 (0.3%) classified incorrectly, and 5/288 (1.7%) were indeterminate. HGMS showed a sensitivity of 98.76% and specificity of 99.65% in determining benign vs malignant. Conclusion HGMS proteomic analysis is an objective and reliable test with minimal tissue requirements, which can be a helpful ancillary test in the diagnosis of challenging melanocytic lesions. |
Databáze: | OpenAIRE |
Externí odkaz: |